Vertex announces new drug submission for investigational triple combination medicine for the treatment of cystic fibrosis has been accepted for priority review by health canada

Boston--(business wire)--vertex pharmaceuticals incorporated today announced its new drug submission for trikafta® has been accepted for priority review by health canada.

VRTX Ratings Summary

VRTX Quant Ranking